Skip Navigation


Issue No. 41 | October 03, 2008
A Service of the U.S. Department of Health and Human ServicesView HTML version
News and Features 

CDC Publishes Estimated Prevalence of HIV Infection in the United States

"CDC's analysis reveals that more than a million people - an estimated 1,106,400 adults and adolescents - were living with HIV infection in the United States at the end of 2006. This analysis also reveals some important news about progress in our nation's fight against HIV/AIDS."

Read the full report here and a Q&A on the new estimate.

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Releases 2006 Disease Profile Report

"This report includes a review of HIV/AIDS, viral hepatitis, STD, and TB surveillance data, and a special focus section on African-American men to illustrate how these diseases and the factors that influence them may overlap and result in excess disease burden among certain populations."

Read the full report here. [PDF]

FDA Approves New Pediatric Label Changes for Didanosine (Videx EC)

"On September 29, 2008, FDA approved a pediatric efficacy supplement for Videx EC (didanosine) Delayed-Release Capsules, expanding the indication to include children weighing at least 20 kg."

The updated label will be available from the FDA soon. More information is available:

FDA Approves Alternative Dosing Regimen for Atazanavir (Reyataz) in Treatment-Naive Patients

"On September 30, 2008, FDA approved an alternative dosing regimen for Reyataz (atazanavir) for HIV-1 infected treatment-naive patients who can take ritonavir. The recommended dosage is Reyataz 300 mg with ritonavir 100 mg once daily for treatment-naive patients."

The updated label will be available from the FDA soon. More information is available:

  • FDA: Atazanavir Label and Approval History
  • AIDSinfo: Atazanavir Drug Fact Sheet
  • AIDSinfo: Adult Treatment Guidelines

Emergence of HIV/AIDS Traced to Colonial-Era Africa

"New research suggests that AIDS among humans occurred at least three decades earlier than previously thought."

Read the full story.

Study: Once-Daily Boosted Darunavir Similar to Twice-Daily for Some Patients

"Treatment-experienced, HIV-infected patients with no baseline darunavir RAMs achieved similar high responses with darunavir/r 800/100 mg once daily and 600/100 mg twice daily."

More information is available:

  • PubMed: Study Abstract
  • AIDSinfo: Darunavir Drug Fact Sheet

Study: Ezetimibe Reduces LDL Cholesterol in Patients Receiving HAART

"Ezetimibe was safe and effective in reducing low-density lipoprotein cholesterol and is an option for patients who cannot tolerate treatment with a statin."

For more information, read the study abstract.

Study: Anti-Obesity Treatments May Fight Viral Infections

"Drugs used to treat obesity may be effective against a wide range of viral infections such as the flu, hepatitis, and even HIV ... ."

For more information, read the full story.

Study: Three Million Injection Drug Users Could Be HIV-Positive

"As the number of countries reporting intravenous drug use has increased over the last decade, a new study suggests that as many as 3 million of these addicts may be HIV-positive."

For more information, read the full story.

Home | Guidelines | Clinical Trials | Drugs | Health Topics | Education Materials | Mobile Resources & Tools
Contact Us
Left footer corner image Left footer corner image